Theraclone Sciences, Inc. Presents Positive Data from Phase 1 Trial of Therapeutic Antibody for the Treatment of Human Cytomegalovirus Infection at ICAAC 2013
Published: Sep 11, 2013
SEATTLE--(BUSINESS WIRE)--Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced that it presented the full, positive data from its Phase 1 trial of TCN-202 for the treatment of human cytomegalovirus (CMV) infections at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 10-13, 2013, in Denver, Colorado. TCN-202 is a recombinant fully human monoclonal antibody discovered using the Company’s proprietary I-STAR™ platform. TCN-202 was well tolerated throughout the study, with no dose-limiting toxicities or serious adverse events observed, and demonstrated a favorable immunogenicity profile.
Help employers find you! Check out all the jobs and post your resume.